How to self administer Tirzepatide "Mounjaro" for Diabetes & Weight Management

Process Overview

Supplies you will need:

1. Tirzepatide 10mg

2. Reconstitution Solution

3. U100 Insulin Syringe 30G x 5/16" 8mm

4. Alcohol Wipes

Preparing the Vials:

1. Sanitize everything

2. Transfer the water into the powder

3. Swirl gently to mix. Avoid vigorous shaking

4. Check the solution is clear and fully mixed.

Measuring Your Dose:

1. Insert the needle into the vial, invert, and draw the protocol's dose

2. Remove air bubbles by tapping the syringe and pushing any air out.

3. Proceed with injection into your stomach

Starting Dose - 75 once a week for 4 weeks

U100 (1ml) Syringe

10mg Vial

3ml of Water

75 per Dose

Dose Increase - start at 40 and increase slightly during weeks 5-8, weeks 9-12, and weeks 13-16, and eventually reach 50 on week 17 then onwards to find your body tolerance.

U100 (1ml) Syringe

10mg Vial

1ml of Water Notice the water decrease here. You can add water to the syringe to dilute it before injecting to avoid pain.

50 per Dose

How to Inject Yourself

Protocol Explanation

The recommended Mounjaro dosing protocol begins with a 2.5mg weekly dose for the first four weeks to assess tolerability and initial effects. From weeks 5 to 24, the dose should be increased to 5mg per week, with adjustments of 2.5mg increments based on the patient's response, aiming for optimal weight loss while minimizing side effects. Tirzepatide is administered via subcutaneous injection once weekly, aligning with its pharmacokinetics for sustained efficacy.

The protocol suggests a duration of 12 to 24 weeks to thoroughly evaluate the drug's safety and weight loss efficacy. The maximum established weekly dose is 15mg, and exceeding this may lead to adverse effects.

Side Effects

Minor side effects, mostly gastrointestinal, such as nausea, vomiting, diarrhea, and abdominal pain, are common but typically subside with dosage adjustment or therapy discontinuation.

The drug is FDA-approved for treating type 2 diabetes in adults, underscoring its safety. Clinical trials, including the SURPASS-1 and SURPASS-4, have confirmed its safety profile comparable to other GLP-1 receptor agonists and have not identified increased cardiovascular risks. Ongoing research under the SURMOUNT program further supports its potential as a weight loss treatment with a favorable safety profile.

However, tirzepatide is contraindicated in individuals with a history of specific thyroid cancers or conditions due to potential risks identified in rodent studies. Caution is advised when used alongside insulin or drugs with a narrow therapeutic index, due to possible hypoglycemia or delayed medication absorption.

Tips and Tricks

-Always use a new syringe for everything, mixing, administering, or transferring. This avoids any contamination.

-Sanitize everything, your hands, the vial tops, and your skin. This will avoid infection.

-If the peptide doesn't fully mix, swirl it a bit or set it in lukewarm water for a minute, then swirl gently again.

Storge

-Powder should be stored in freezer -Once reconstituted then store the liquid peptide in the Refrigerator

Emergency Protocol

In the event of experiencing severe side effects from Semaglutide, follow this emergency protocol to ensure swift and appropriate action:

1. Identify Severe Symptoms

Anaphylaxis signs: Sudden swelling of face, lips, throat, difficulty breathing, rapid heartbeat, dizziness, or weakness.

Severe Hypoglycemia: Confusion, seizures, loss of consciousness, extreme weakness, blurred vision.

Signs of serious infection at the injection site: Increasing redness, swelling, warmth, discharge, or fever.

Symptoms of gallbladder problems: Intense abdominal pain, jaundice (yellowing of the skin or eyes), high fever.

2. Immediate Actions

For anaphylaxis or severe hypoglycemia: Administer an epinephrine injection if available and immediately call emergency services or go to the nearest emergency room.

For severe injection site reactions or suspected infections: Contact a healthcare provider promptly for evaluation.

For symptoms of gallbladder or renal issues: Seek urgent medical attention.

3. Supportive Measures

For mild to moderate hypoglycemia: Consume a fast-acting carbohydrate (glucose tablets, fruit juice, candy) and follow up with a snack or meal.

For nausea or dehydration: Increase fluid intake, consider over-the-counter antinausea medication if previously advised by a healthcare provider, and rest.

4. Documentation

Document the time the medication was taken, when symptoms began, and any actions taken in response. This information is crucial for healthcare providers to determine the best course of action.

5. Consultation and Follow-Up

After addressing immediate concerns, consult with a healthcare provider for a thorough evaluation and guidance on whether to continue or adjust Tirzepatide treatment.

6. Prevention and Preparedness

-Always have access to emergency contact numbers and an epinephrine.

-Educate yourself and close contacts on recognizing severe side effects and the steps to take in an emergency.

Disclaimer

This protocol is provided for informational purposes only and does not constitute medical advice. It is intended to offer general guidelines for managing potential severe side effects associated with Tirzepatide use. The information contained herein should not be used as a substitute for the advice of a licensed healthcare professional. Individual responses to Tirzepatide can vary significantly, and not all side effects or emergencies can be anticipated. It is crucial to consult with a healthcare provider for personalized guidance tailored to your specific health condition and treatment plan. Always follow the instructions provided by your healthcare provider and the medication's manufacturer. The creators of this protocol assume no responsibility for any errors or omissions in the content provided or for the results obtained from the use of this information. Users are encouraged to seek immediate medical attention in the event of any adverse reactions or uncertainties. By utilizing this protocol, users acknowledge and agree that the creators and distributors of this guide shall not be liable for any damages arising from or in connection with the use of the information provided. Always keep emergency contact information readily available and inform your healthcare provider of any concerns related to your treatment with Semaglutide.